Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03489343 · ClinicalTrials.gov registry record · Phase 1

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

A Phase 1 study of Lymphoma and Solid Tumor, sponsored by Symphogen A/S.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
4
Study locations

NCT03489343 is a Phase 1 study of Lymphoma and Solid Tumor that has completed, run by Symphogen A/S. The registered enrollment target is 24 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03489343, a Phase 1 study of Lymphoma and Solid Tumor, has completed, sponsored by Symphogen A/S.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
4
Study locations

Study Summary

This was the first study to test Sym023 in humans. The primary purpose of this study was to see if Sym023 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.

Conditions Studied

Lymphoma Solid Tumor Metastatic Cancer

Interventions

  • DRUG Sym023

Study Locations (4)

Texas

  • The University of Texas MD Anderson Cancer Center - Houston
  • NEXT Oncology - San Antonio

Michigan

  • South Texas Accelerated Research Therapeutics (START) Midwest - Grand Rapids

Ontario

  • Princess Margaret Cancer Centre - Toronto

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2018-05-24
Est. Completion 2020-06-03
Phase Phase 1

Sponsor

Symphogen A/S

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03489343

The ClinicalTrials.gov registry entry for NCT03489343 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The listed sponsor is Symphogen A/S, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Sym023 is the first listed.

NCT03489343 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, Michigan, Ontario.

Frequently Asked Questions

What is clinical trial NCT03489343 about?

NCT03489343 is a clinical study titled "Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas". This was the first study to test Sym023 in humans. The primary purpose of this study was to see if Sym023 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therap...

What is the current status of trial NCT03489343?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-05-24. Estimated completion is 2020-06-03.

What conditions does trial NCT03489343 study?

This clinical trial studies the following conditions: Lymphoma, Solid Tumor, Metastatic Cancer.

What interventions are being tested in trial NCT03489343?

The interventions under investigation include: Sym023 (DRUG).

Who is sponsoring clinical trial NCT03489343?

This trial is sponsored by Symphogen A/S, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03489343 being conducted?

This trial has 4 study locations across Michigan, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Solid Tumor

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.